CN104490965A - Application of panax japonicus polysaccharide, total saponins of panax japonicus and panax japonicus saponin V - Google Patents
Application of panax japonicus polysaccharide, total saponins of panax japonicus and panax japonicus saponin V Download PDFInfo
- Publication number
- CN104490965A CN104490965A CN201410721839.4A CN201410721839A CN104490965A CN 104490965 A CN104490965 A CN 104490965A CN 201410721839 A CN201410721839 A CN 201410721839A CN 104490965 A CN104490965 A CN 104490965A
- Authority
- CN
- China
- Prior art keywords
- panax japonicus
- group
- panacis japonici
- rhizoma panacis
- total saponins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Abstract
The invention discloses an application of panax japonicus polysaccharide, total saponins of panax japonicus, panax japonicus saponin V and a composition of panax japonicus polysaccharide and total saponins of panax japonicus in preparation of medicines for preventing and treating chronic obstructive pulmonary disease. The medicine containing the components is less in side effect, is originated from a single plant, is simple in component, and is definite in curative effect for preventing and treating COPD.
Description
Technical field
The invention belongs to drug world, be specifically related to Rhizoma Panacis Japonici polysaccharides, panax japonicus total saponins and the Rhizoma Panacis Japonici saponin V application in medicine preparation.
Background technology
Chronic obstructive pulmonary disease (chronic obstructive pulmonary disease, COPD) be a kind of there is flow limitation feature can the disease of prevention and therapy, flow limitation is not exclusively reversible, develop in Progressive symmetric erythrokeratodermia, react relevant with the abnormal inflammatory of pulmonary to the harmful gass such as smoke from cigarette or deleterious particle, its chronic inflammatory reaction is throughout air flue, pulmonary parenchyma and Pulmonary Vascular.COPD mainly involves lungs, but also can cause the ill effect of whole body (or claiming outside lung).
COPD is chronic disease common in a kind of global range, is number four at present in the global cause of death, and according to World Health Organization's prediction, to the year two thousand twenty, COPD will be number five in global disease morbidity, be number three in the cause of death.In recent years, the sickness rate of China COPD is in rising trend, and the prevalence of more than 40 years old crowd is 9% ~ 10%, and within more than 60 years old, prevalence is up to 13% ~ 30%, and the whole nation is every year because the number of COPD death reaches 1,000,000.
The common clinical manifestation of COPD has chronic cough, expectoration, breathe hard or dyspnea, to pant and the symptom such as uncomfortable in chest, in the clinical course of disease, special in heavier patient, systemic symptoms may be there is, as weight loss, loss of appetite, periphery amyotrophy and dysfunction, spirit depressing and (or) anxiety etc.
The pathogenesis of COPD is not yet completely clear.Generally believe that the cell participating in COPD has the inflammatory cells such as neutrophilic granulocyte, T lymphocyte and macrophage at present, multiple inflammatory mediator is discharged after cell is activated, as leukotriene B4 (LTB4), interleukin 8 (IL-8), tumor necrosis factor α (TNF-α), GELB (MMP-9) etc., participate in the inflammatory reactions such as pulmonary parenchyma destruction, Pulmonary Vascular.Its pathological change feature shows as alveolar space inflammatory cell (as macrophage) infiltration, bronchia and peribronchiolar stove inflammatory cell infiltration, the alveolar space expansion of lung tissue edge, destruction, alveolar wall broadens, its epithelial cell swelling, change circle, partial exfoliation.
At present, the treatment of COPD mainly comprises bronchodilators, glucocorticoid, antibiotic, oxygen therapy and mechanical ventilation etc.Data shows, medicine energy mitigation symptoms, increase motor capacity, minimizing acute episode frequency and the order of severity, and improve health status and exercise tolerance, but these side effects of pharmaceutical drugs are very large, therefore, eager needs develop and come from single plant, and composition is simple, the effective site of clear curative effect, effective ingredient or active component, for preventing and treating COPD.
Summary of the invention
In order to solve the problems of the technologies described above, the invention provides the application of compositions in the medicine preparing prevention and therapy chronic obstructive pulmonary disease of Rhizoma Panacis Japonici polysaccharides, panax japonicus total saponins or Rhizoma Panacis Japonici polysaccharides and panax japonicus total saponins.
Preferably, in above-mentioned composition, the mass ratio of Rhizoma Panacis Japonici polysaccharides and panax japonicus total saponins is 1:3 ~ 3:1.Further preferably, the mass ratio of Rhizoma Panacis Japonici polysaccharides and panax japonicus total saponins is 1:1
Present invention also offers the application of Rhizoma Panacis Japonici saponin V in the medicine preparing prevention and therapy chronic obstructive pulmonary disease.
Present invention also offers a kind of medicine of prevention and therapy chronic obstructive pulmonary disease, one of them or compositions containing Rhizoma Panacis Japonici polysaccharides or panax japonicus total saponins.
Preferably, in above-mentioned composition, the mass ratio of Rhizoma Panacis Japonici polysaccharides and panax japonicus total saponins is 1:3 ~ 3:1.More preferably, in above-mentioned composition, the mass ratio of Rhizoma Panacis Japonici polysaccharides and panax japonicus total saponins is 1:1.
Further, also pharmaceutically acceptable carrier can be contained in above-mentioned medicine.
Present invention also offers a kind of medicine of prevention and therapy chronic obstructive pulmonary disease, containing Rhizoma Panacis Japonici saponin V.
Further, also pharmaceutically acceptable carrier can be contained in said medicine.
Pharmaceutically acceptable carrier comprises the adjuvant of oral formulations adjuvant or Parenteral.Route of administration can be oral, injection, topical etc.According to technical scheme of the present invention, said composition can be oral formulations or injection preparation, and wherein oral formulations comprises capsule, soft capsule, granule, oral liquid, tablet, drop pill etc.Adjuvant used comprises: the customary adjuvant such as starch, sucrose, lactose, Icing Sugar, glucose, mannitol, xylitol, Polyethylene Glycol, isopropyl alcohol, Ye Wen-80, glycerol, propylene glycol, microcrystalline Cellulose sodium, dextrin, cyclodextrin, sodium chloride, vitamin C, half skin propylhomoserin, citric acid, sodium thiosulfate, sodium sulfite, stearate and gelatin, preparation later stage preparation technology and equipment all belong to the routine techniques of pharmaceutical field, the present invention is not construed as limiting this, therefore will not describe in detail at this.
In application of the present invention the compositions of Rhizoma Panacis Japonici polysaccharides, panax japonicus total saponins, Rhizoma Panacis Japonici polysaccharides and panax japonicus total saponins or Rhizoma Panacis Japonici saponin V tool be significantly improved that the pulmonary function of the mice COPD model that lipopolysaccharide and medicated cigarette are induced jointly is low, flow limitation and cough, breathe heavily, uncomfortable in chest etc., and side effect is little, come from single plant, composition is simple, for preventing and treating COPD clear curative effect.
Rhizoma Panacis Japonici polysaccharides of the present invention, panax japonicus total saponins and Rhizoma Panacis Japonici saponin V therefrom extract in medical bamboo JIESHEN and obtain.Rhizoma Panacis Japonici is conventional Chinese herbal medicine, and have long-term traditional Chinese medical science medication experience, this medicine is safe to use, records without overt toxicity effect.
Rhizoma Panacis Japonici polysaccharides, panax japonicus total saponins, its compositions and Rhizoma Panacis Japonici saponin V have that definite improvement animal pattern pulmonary function is low, flow limitation and cough, the effect of to breathe heavily etc.Therefore, Rhizoma Panacis Japonici polysaccharides, panax japonicus total saponins and Rhizoma Panacis Japonici saponin V have the prospect being developed to and preventing with treatment COPD medicine.
Detailed description of the invention
Below in conjunction with specific embodiment, the invention will be further described, can better understand the present invention and can be implemented, but illustrated embodiment is not as a limitation of the invention to make those skilled in the art.
Rhizoma Panacis Japonici is the dry root of Araliaceae Panax herbaceos perennial Panax japonicus C. A. Mey..Former is a kind of famous and precious Chinese herbal medicine among the people, begins to be loaded in supplementary Amplifications of the Compendium of Materia Medica, has now recorded in the Pharmacopoeia of the People's Republic of China, the similar Radix Ginseng of medicinal function and Radix Notoginseng.Rhizoma Panacis Japonici is born in by hillside limes marginis, dark and damp area or rock ditch ravine.Mainly be distributed in the ground such as Guizhou, Hunan, Yunnan, Anhui, Jiangxi, Hubei.Annual autumn excavates, and removing stem and leaf, separates fleshy tap root, rhizome is removed crust, dry or dry in the shade and can be used as medicine.Rhizoma Panacis Japonici sweet in the mouth, micro-hardship, warm in nature, there is the multiple efficacies such as blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, strengthening by means of tonics.The strengthening by means of tonics effect of existing similar Radix Ginseng, has again the eliminating stasis to stop pain of similar Radix Notoginseng, hemostasis, phlegm-dispelling functions, is mainly used in weakness, chronic cough hemoptysis, cough with copious phlegm, traumatic injury etc. after being ill.Containing multiple saponin, volatile oil, saccharide and several amino acids class chemical composition in Rhizoma Panacis Japonici.
The extraction of embodiment one Rhizoma Panacis Japonici polysaccharides, purification and preparation
Get Rhizoma Panacis Japonici coarse powder, add the water of 10 times amount, soak after 2 hours, decoct extraction 2 hours, filter, obtain filtrate.The water boiling and extraction 2 times of 8 times amount used again by medicinal residues, each 1.5 hours, filters.Merge 3 filtrates, be evaporated to appropriate volume.In high concentration ethanol to concentrated solution to concentration of alcohol be 65%, under room temperature place more than 12 hours, filter, collecting precipitation thing, repeatedly precipitate with ethanol 2 times, merge precipitate, through lyophilization, obtain Rhizoma Panacis Japonici polysaccharides.
The extraction of embodiment two panax japonicus total saponins, purification and preparation
Get Rhizoma Panacis Japonici coarse powder, add the ethanol of 60% of 10 times amount, soak 2 hours, water-bath reflux, extract, 2 hours, filter, obtain filtrate.The alcohol reflux 2 times of 60% of 8 times amount used again by medicinal residues, each 1.5 hours, filters.Merge 3 filtrates, decompression recycling ethanol, to without alcohol taste, is mixed with medical material: the solution that medicinal liquid (g/m1) is 1:2.5.On the HP-400 macroporous resin column handled well, use successively water, 60% ethanol elution.Merge the ethanol elution of 60%, recycling design, near dry, through lyophilization, obtains panax japonicus total saponins.
The extraction of embodiment three Rhizoma Panacis Japonici saponin V, purification and preparation
Get Rhizoma Panacis Japonici coarse powder, add the ethanol of 60% of 10 times amount, soak after 2 hours, reflux, extract, 2 hours, filter, obtain filtrate, the alcohol reflux 2 times of 60% of 8 times amount used again by medicinal residues, each 1.5 hours, filters.Merge three filtrates, decompression recycling ethanol, to without alcohol taste, is mixed with medical material: the solution that medicinal liquid (g/ml) is 1:2.5.On the HPD-400 macroporous resin column handled well, use successively water, 60% ethanol elution.Merge the ethanol elution of 60%, recycling design is closely dry, through 65 DEG C of drying under reduced pressure, obtains panax japonicus total saponins.Panax japonicus total saponins is again through HP-20 resin column purification, and collect the ethanol elution of 55% ~ 85%, decompression recycling ethanol, lyophilization, obtains Rhizoma Panacis Japonici saponin V, and its purity is greater than 90%.
Embodiment four
Rhizoma Panacis Japonici polysaccharides, panax japonicus total saponins and Rhizoma Panacis Japonici saponin V prevent the experimentation with treatment COPD
1. experiment material
1. 1 medicine and reagent
Terbutaline sulphate sheet (HaiNan Kangzhi Pharmaceutical Co., Ltd, lot number 131116); Lipopolysaccharide (LPS, Sigma Co., USA); Malonaldehyde (MDA) and superoxide dismutase (SOD) test kit (Bioengineering Research Institute is built up in Nanjing); Tumor necrosis factor α (TNF-α) and IL-10 (IL-10) test kit (Wuhan Boster Biological Technology Co., Ltd.); Rhizoma Panacis Japonici polysaccharides (DT), panax japonicus total saponins (ZG), Rhizoma Panacis Japonici saponin V(ZV) make by oneself for this laboratory.
1. 2 experimental apparatus
The long multi-functional microplate reader (model SAFIRE2) of TE-CAr all-wave; LXJ-II centrifuge (Shanghai medical analytical instrument factory); Satrious electronic balance (Germany); Thermostat water bath (Shanghai Yarong Biochemical Instrument Plant); Low-temperature and high-speed centrifuge (the beautiful Z323K in sky); RSFJ800 lung function measuring equipment (Chengdu Sheng Science and Technology Ltd.); Liquid-transfering gun (big dragon).
1.3 laboratory animal
Healthy cleaning grade Wistar rat 56, male, body weight 200g ± 20g, is provided by Central China University of Science and Technology's animal center.
2. the preparation of laboratory sample
The Rhizoma Panacis Japonici polysaccharides prepared in embodiment one, two, three, panax japonicus total saponins and Rhizoma Panacis Japonici saponin V.
3. the preparation of test specimen liquid
3.1. the preparation of CMC-Na solution: precision takes 4 g CMC-Na and is dissolved in 1000 mL distilled water, is mixed with the CMC-Na solution that concentration is 0. 4%.
3.2. positive control solution preparation: take terbutaline sulphate sheet appropriate, being placed in mortar and being ground into fine powder, be dissolved in the addition of C MC-Na solution, obtain the terbutaline sulphate suspension of 0.1mg/ml, is positive control medicinal liquid.
3.3. the preparation of DT medicinal liquid: it is appropriate that precision takes DT.Be dissolved in the addition of C MC-Na solution, obtain the DT suspension of 2.0 mg/ml.
3.4. the preparation of ZG medicinal liquid: it is appropriate that precision takes ZG.Be dissolved in the addition of C MC-Na solution, obtain the ZG suspension of 2.0 mg/ml.
3.5.ZV the preparation of medicinal liquid: it is appropriate that precision takes ZV.Be dissolved in the addition of C MC-Na solution, obtain the ZV suspension of 1.0 mg/ml.
3.6. DT+ZG(1) preparation of medicinal liquid: it is appropriate that precision takes ZG and DT.Be dissolved in the addition of C MC-Na solution, the suspension of 1.0 and 1.0 mg/ml must be respectively containing DT and ZG.(i.e. DT:ZG=1:1)
3.7. DT+ZG(2) preparation of medicinal liquid: it is appropriate that precision takes ZG and DT.Be dissolved in the addition of C MC-Na solution, the suspension of 1.5 and 0.5 mg/ml must be respectively containing DT and ZG.(i.e. DT:ZG=3:1)
3.8. DT+ZG(3) preparation of medicinal liquid: it is appropriate that precision takes ZG and DT.Be dissolved in the addition of C MC-Na solution, the suspension of 0.5 and 1.5 mg/ml must be respectively containing DT and ZG.(i.e. DT:ZG=1:3)
4. experimental technique
4.1 animal groupings: healthy cleaning grade Wistar rat 72, male, body weight 200g ± 20g, by body weight be divided at random normal group, model group, positive group, DT group, ZG group, ZV group, DT+ZG(1) group, DT+ZG(2) group and DT+ZG(3) group, the all free diet of each treated animal, adaptability is raised after one week for experiment.
4.2 animal models: adopt tracheal strips to inject lipopolysaccharide (LPS) and superpose fumigation associating modeling.Model group, treatment group were at the 1st day, pentobarbital sodium (0. 5ml/100g) intraperitoneal injection of anesthesia with 0.7%, dorsal position is fixed on rat fixing head, expose glottis, by No. 18 venous catheter needle quick insertion tracheas, extract nook closing member, inject the LPS 200 μ L (1 mg/1ml) being dissolved in normal saline with 1 ml syringe, then by rat fixing head vertical rotary, LPS is enable to be uniformly distributed in two lungs; Normal group implements sham-operation saline injection.Rat was inserted in 60cm × 50cm × 40cm lucite case in 2nd ~ 56 days, inject cigarette with filter tip, smoke from cigarette concentration about 5 % (vPv), every morning, afternoon each 1h.
4.3 animals administers: adopt gastric infusion mode, normal group and model group give the CMC-Na solution of 10 ml/kg, each administration group gives the medicinal liquid of 10 ml/kg respectively, namely the dosage being equivalent to positive group is 1 mg/kg, DT be 20 mg/kg, ZG be 20 mg/kg, ZV groups is 10 mg/kg, DT+ZG(1) group, DT+ZG(2) group and DT+ZG(3) be 20 mg/kg, successive administration 56 days.
4.4 detect: last 1 administration is after 2 hours, and in rat eyeground vein clump blood sampling about 1.2 m1, separation of serum (4000rp/min, 10min, 4 DEG C), ELISA kit measures the indexs such as MDA, SOD, TNF-α, IL-10.After blood sampling, all animals with 0. 7% pentobarbital sodium according to 0. 5ml/100g intraperitoneal injection of anesthesia, after anesthesia, be separated trachea, cut the otch of falling T-shape the three or four in the middle of annulus trachealis, then tracheal intubation is inserted in trachea, then tight by linear system.Body animal being put into lung function measuring equipment retouches case, tracheal intubation and body is retouched case gas circuit and is connected.Measure rat 0. 1 seconds forced expiratory volume (FEV
0.1), FEV
0.1with the ratio percent (FEV of FVC
0.1/ FVC %), 0. 3 seconds forced expiratory volume (FEV
0.3), FEV
0.3with the ratio percent (FEV of FVC
0.3/ FVC %).
5. statistical method
(x ± S} represents each group of experimental data mean ± standard deviation, and carries out statistical procedures with SPSS 13.0, and significance test adopts variance analysis.
6. result and discussion
Table 1. is group rat FEV respectively
0.1, FEV
0.1/ FVC compares (x ± s)
| Group | Number of cases | FEV 0.1(L) | FEV 0.1 (L)/FVC(%) |
| Normal group | 5 | 1.58±0.12 | 24.25±1.36 |
| Model group | 5 | 1.24±0.24 ## | 18.52±2.31 ## |
| Positive group | 6 | 1.56±0.18 ** | 23.49±2.27 ** |
| DT group | 5 | 1.45±0.22 ** | 22.38±3.32 ** |
| ZG group | 6 | 1.42±0.30 * | 22.08±2.87 * |
| ZV group | 5 | 1.47±0.16 ** | 23.20±4.57 ** |
| DT+ZG group (1) | 6 | 1.55±0.24 *** | 24.03±3.28 *** |
| DT+ZG group (2) | 6 | 1.50±0.22 ** | 21.32±3.64 ** |
| DT+ZG group (3) | 6 | 1.52±0.20 ** | 23.53±2.78 ** |
Note: compare with normal group, #P < 0. 05; Compare with model group, * P<0.05.
Table 2: each group rat FEV
0.3, FEV
0.3/ FVC compares (x ± s)
| Group | Number of cases | FEV 0.3(L) | FEV 0.3 (L)/FVC(%) |
| Normal group | 5 | 6.12±0.36 | 91.36±10.81 |
| Model group | 5 | 4.87±0.28 ## | 78.83±8.48 ## |
| Positive group | 6 | 5.62±0.43 ** | 86.02±7.04 ** |
| DT group | 5 | 5.45±0.21 ** | 85.44±9.31 ** |
| ZG group | 6 | 5.22±0.58 * | 82.87±9.95 * |
| ZV group | 5 | 5.38±0.49 ** | 84.99±7.24 ** |
| DT+ZG group (1) | 6 | 5.98±0.52 *** | 89.73±7.62 *** |
| DT+ZG group (2) | 6 | 5.24±0.52 ** | 83.73±6.62 ** |
| DT+ZG group (3) | 6 | 5.14±0.52 ** | 85.73±7.21 ** |
Note: compare with normal group, #P < 0. 05; Compare with model group, * P<0.05.
From table 1 and table 2, there is obvious flow limitation in model group compared with normal group, and after administration is intervened, flow limitation degree is minimized, and shows that each medicine group has significant improvement result to COPD rat model pulmonary function, truly has curative effect.
Table 3: Content of MDA, SOD vitality test (x ± s)
| Group | Number of cases | MDA(U/ml) | SOD(U/ml) |
| Normal group | 8 | 4.41±1.56 | 72.57±8.29 |
| Model group | 8 | 9.33±3.96 ## | 62.49±9.89 ## |
| Positive group | 7 | 6.38±1.26 ** | 71.54±6.40 ** |
| DT group | 8 | 7.30±1.77 * | 69.25±4.35 * |
| ZG group | 8 | 7.22±2.65 * | 70.68±8.51 * |
| ZV group | 8 | 6.51±0.71 ** | 71.96±6.85 ** |
| DT+ZG group (1) | 8 | 5.41±0.82 *** | 74.27±8.28 *** |
| DT+ZG group (2) | 8 | 6.89±0.62 ** | 70.27±6.97 ** |
| DT+ZG group (3) | 8 | 6.46±0.75 ** | 68.27±7.53 ** |
Note: compare with normal group, #P < 0. 05; Compare with model group, * P<0.05.
As shown in Table 3, it is unbalance to there is obvious oxidation one anti-oxidation stress in COPD rat model group, and it is unbalance that each medicinal part of Rhizoma Panacis Japonici can intervene adjustable body internal oxidition, alleviates oxidative damage.This may be that each administration group improves one of mechanism of rat model flow limitation.
Table 4: TNF-α, IL-10 measurement result (x ± s)
| Group | Number of cases | TNF-α (OD value) | IL-10 (OD value) |
| Normal group | 8 | 0.35±0.21 | 0.28±0.04 |
| Model group | 8 | 0.97±0.20 ## | 0.19±0.04 ## |
| Positive group | 7 | 0.54±0.12 ** | 0.26±0.03 ** |
| DT group | 8 | 0.69±0.22 ** | 0.27±0.04 ** |
| ZG group | 8 | 0.57±0.14 * | 0.26±0.03 ** |
| ZV group | 8 | 0.60±0.12 ** | 0.27±0.04 ** |
| DT+ZG group (1) | 8 | 0.44±0.13 *** | 0.28±0.03 ** |
| DT+ZG group (2) | 8 | 0.60±0.10 ** | 0.24±0.06 ** |
| DT+ZG group (3) | 8 | 0.54±0.09 ** | 0.25±0.05 ** |
Note: compare with normal group, #P < 0. 05; Compare with model group, * P<0.05.
As shown in Table 4, compared with normal group, model group rats serum TNF-cc level obviously raises, IL-10 level obviously reduces, and difference has significance (P<0.01); Compare with model group, obviously can reduce TNF-alpha content after each administration group treatment, raise IL-10 content, difference has significance (P<0.01 or P<0.05), shows that each administration group can reduce inflammation the damage of factor pair lung tissue.
In sum, the mixture of panax japonicus total polysaccharide, panax japonicus total saponins, Rhizoma Panacis Japonici saponin V and panax japonicus total polysaccharide and panax japonicus total saponins all effectively can alleviate the flow limitation of COPD, control COPD cause uncomfortable in chest, breathe heavily, the symptom such as dyspnea, its mechanism can may regulate the damage of unbalance, the nitric oxide production generation of the vivo oxidation of COPD and the factor pair lung tissue that reduces inflammation relevant with Rhizoma Panacis Japonici polysaccharides and Rhizoma Panacis Japonici saponin, and being 1:1 with the ratio of panax japonicus total polysaccharide and panax japonicus total saponins, mixture drug effect is best.
The above embodiment is only that protection scope of the present invention is not limited thereto in order to absolutely prove the preferred embodiment that the present invention lifts.The equivalent alternative or conversion that those skilled in the art do on basis of the present invention, all within protection scope of the present invention.Protection scope of the present invention is as the criterion with claims.
Claims (10)
1. the application of compositions in the medicine preparing prevention and therapy chronic obstructive pulmonary disease of Rhizoma Panacis Japonici polysaccharides, panax japonicus total saponins or Rhizoma Panacis Japonici polysaccharides and panax japonicus total saponins.
2. application according to claim 1, is characterized in that, in described compositions, the mass ratio of Rhizoma Panacis Japonici polysaccharides and panax japonicus total saponins is 1:3 ~ 3:1.
3. application according to claim 2, is characterized in that, in described compositions, the mass ratio of Rhizoma Panacis Japonici polysaccharides and panax japonicus total saponins is 1:1.
4. the application of Rhizoma Panacis Japonici saponin V in the medicine preparing prevention and therapy chronic obstructive pulmonary disease.
5. a medicine for prevention and therapy chronic obstructive pulmonary disease, is characterized in that, one of them or compositions containing Rhizoma Panacis Japonici polysaccharides or panax japonicus total saponins.
6. medicine according to claim 5, is characterized in that, in described compositions, the mass ratio of Rhizoma Panacis Japonici polysaccharides and panax japonicus total saponins is 1:3 ~ 3:1.
7. medicine according to claim 5, is characterized in that, in described compositions, the mass ratio of Rhizoma Panacis Japonici polysaccharides and panax japonicus total saponins is 1:1.
8. the medicine according to any one of claim 5 ~ 7, is characterized in that, also containing pharmaceutically acceptable carrier.
9. a medicine for prevention and therapy chronic obstructive pulmonary disease, is characterized in that, containing Rhizoma Panacis Japonici saponin V.
10. medicine according to claim 9, is characterized in that, also containing pharmaceutically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410721839.4A CN104490965B (en) | 2014-12-03 | 2014-12-03 | The application of panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410721839.4A CN104490965B (en) | 2014-12-03 | 2014-12-03 | The application of panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104490965A true CN104490965A (en) | 2015-04-08 |
| CN104490965B CN104490965B (en) | 2017-08-18 |
Family
ID=52932479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410721839.4A Active CN104490965B (en) | 2014-12-03 | 2014-12-03 | The application of panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104490965B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106880654A (en) * | 2017-04-11 | 2017-06-23 | 中南民族大学 | Application and composition of the ring conopsea extraction in treatment rhinitis medicine is prepared |
| CN115611995A (en) * | 2022-12-05 | 2023-01-17 | 东北师范大学 | Panax japonicus polysaccharide and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247391A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Application of panax japonicus saponin V to reduction of blood fat |
| CN102247417A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Fat reduction effect of total saponins and polysaccharides of Panax japonicus |
| CN102247418A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Liver protection effect of panax japonicus total saponin and panax japonicus polysaccharide |
-
2014
- 2014-12-03 CN CN201410721839.4A patent/CN104490965B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247391A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Application of panax japonicus saponin V to reduction of blood fat |
| CN102247417A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Fat reduction effect of total saponins and polysaccharides of Panax japonicus |
| CN102247418A (en) * | 2010-05-19 | 2011-11-23 | 杨小林 | Liver protection effect of panax japonicus total saponin and panax japonicus polysaccharide |
Non-Patent Citations (4)
| Title |
|---|
| ZHOU JIANG,ET AL.: "Protective Effect of Ginsenoside RO on Anoxic and Oxidative Damage In vitro", 《BIOMOLECULES&THERAPEUTICS》 * |
| 张小鸿等: "竹节参皂苷药理作用研究进展", 《天然产物研究与开发》 * |
| 杨岚等: "慢性阻塞性肺病患者氧化与抗氧化失衡的研究", 《陕西医学杂志》 * |
| 许彬等: "竹节参多糖对小鼠血液SOD、CAT、MDA影响的研究", 《中国医院药学杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106880654A (en) * | 2017-04-11 | 2017-06-23 | 中南民族大学 | Application and composition of the ring conopsea extraction in treatment rhinitis medicine is prepared |
| CN106880654B (en) * | 2017-04-11 | 2020-09-29 | 中南民族大学 | Application of panax japonicus extract in preparing medicine for treating rhinitis and composition |
| CN115611995A (en) * | 2022-12-05 | 2023-01-17 | 东北师范大学 | Panax japonicus polysaccharide and preparation method and application thereof |
| CN115611995B (en) * | 2022-12-05 | 2023-03-17 | 东北师范大学 | Panax japonicus polysaccharide and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104490965B (en) | 2017-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104013668B (en) | Licoflavone class extract is used to prepare to be applied in treatment ulcerative colitis medicine | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN103127273B (en) | Compound medicament for treating chronic liver disease and preparation method thereof | |
| CN104490965A (en) | Application of panax japonicus polysaccharide, total saponins of panax japonicus and panax japonicus saponin V | |
| CN102389496B (en) | Chinese medical composition for treating hepatitis and preparation method thereof | |
| CN107412462B (en) | Preparation method of Huanglong cough and asthma capsule | |
| CN106539908A (en) | A kind of Chinese medicine composition for treating allergic rhinitises and skin allergy | |
| CN104825750B (en) | The preparation of a kind of Flos Ginseng processed and preparation method | |
| CN104095912B (en) | Treat the preparation method of the Chinese patent drug of rheumatism bone disease | |
| CN113694078A (en) | Application of vinegar-roasted schisandra polysaccharide extract in preparation of medicine for treating diabetes | |
| CN103142695B (en) | Pharmaceutical composition for prevention and treatment of chronic glomerular diseases and preparation method of pharmaceutical composition | |
| CN114712478A (en) | Traditional Chinese medicine composition and preparation for treating intestinal diseases and preparation method thereof | |
| CN102247417B (en) | Fat reduction effect of total saponins and polysaccharides of Panax japonicus | |
| CN104435141B (en) | A kind of Chinese medicine composition of the treatment diabetes containing Ramulus euonymi | |
| CN110025011A (en) | A kind of Radix Ophiopogonis ginseng lozenge of strengthen immunity | |
| EP3144003B1 (en) | Application of fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals used for treating coughing | |
| CN113827636B (en) | Lung-clearing mixture containing Tibetan four ingredients and application thereof in preparation of medicines for treating respiratory system diseases | |
| CN115400161B (en) | Traditional Chinese medicine composition for treating summer-heat dampness cold and preparation method thereof | |
| CN102488821A (en) | Traditional Chinese medicine composition for treating bone fracture and preparation method thereof | |
| CN108478701A (en) | A kind of lozenge of strengthen immunity | |
| WO2015172614A1 (en) | Application of fructus schisandrea total lignans in preparation of medicine or nutraceuticals used for treating coughing | |
| CN108324829A (en) | A kind of Hemorrhagic shock mixture and preparation method thereof containing ginseng | |
| CN101181349A (en) | Application of Salvia przewalskii Maxim extract in the preparation of medicament for curing nephritis of renal glomerulus | |
| CN105194234A (en) | Traditional Chinese medicine preparation for treating chronic obstructive pulmonary diseases | |
| CN105168860A (en) | Traditional Chinese medicine composite for treating infantile asthma and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |